4 August 2015

AquaBounty Technologies, Inc.

("AquaBounty" or "the Company")

Interim results for the six months ended 30 June 2015

AquaBounty Technologies, Inc. (AIM: ABTX, ABTU; OTC: AQBT), a biotechnology company focused on enhancing productivity in the aquaculture market, announces its interim results for the six months ended 30 June 2015.

Summary:

·    Raised US$3.0 million through a placing of shares with Intrexon Corporation ("Intrexon");

·    Continued to pursue the approval of its New Animal Drug Application ("NADA") with the US. Food and Drug Administration ("FDA") for AquAdvantage^® Salmon ("AAS"), and the Board remains hopeful that the decision will be received in the near term;

·    Progressed commercial preparations in several foreign markets for field trials of AAS;

·    Net loss for the first six months was unchanged at US$3.5 million (H1 2014: US$3.5 million); and

·    Balance of cash and marketable securities at 30 June 2015 was US$4.7 million (31 December 2014: US$5.2 million).

Ron Stotish, Chief Executive Officer of AquaBounty, commented:

"We remain hopeful that the FDA will approve AAS in the near term, and, while we wait for their decision, we are making significant progress with our marketing efforts and preparations in several foreign markets for field trials. AquaBounty continues to receive interest for AAS from potential customers both within and outside the US, which supports the Board's confidence that the market potential is substantial."

For further information, please contact:

AquaBounty Technologies                                                    +1 978 648 6048

David Frank, Chief Financial Officer

Stifel Nicolaus Europe, Ltd.                                                  +44 (0)20 7710 7499

Giles Balleny

Luther Pendragon                                                                  +44 (0)20 7618 9100

Harry Chathli, Claire Norbury

Operational Review

Update on FDA approval process

The FDA released its preliminary Environmental Assessment ("EA") for AAS, along with a draft Finding of No Significant Impact ("FONSI") on 26 December 2012. This was followed by a 120-day open public comment period, which ended on 26 April 2013. In the 27 months since that time, it has been the Company's understanding that the FDA has been reviewing the comments that it received and that it is in the process of finalising the EA and FONSI. The Company believes that this could potentially lead to an approval of its NADA for AAS later this year.

Since mid-2014, the Company has been moving forward with local regulatory preparations for field trials in several foreign markets. The process has progressed and the trials are planned to commence in 2016.

NASDAQ listing

The Company submitted a registration statement to the SEC (or the "Commission") during 2014 in preparation for a listing of its common shares on NASDAQ and received no further comments from the Commission. However, the Company's shares are currently ineligible for admission to NASDAQ as they do not meet the initial listing requirements. The Board continues to consider its options for resolving this issue and hopes to be able to fulfill the criteria for listing on NASDAQ in the coming months.

Financial Review

On 30 June 2015, AquaBounty completed a fundraising of US$3.0 million by means of an equity placing to its majority shareholder, Intrexon. The proceeds will provide the Company with sufficient cash resources to continue operating to early 2016 at its current rate of spending.

Operating expenses for the six-month period ended 30 June 2015 remained stable at US$3.5 million (H1 2014: US$3.5 million), though there was a shift in functional spending reflecting the Company's preparations for commercialisation. Spending on sales and marketing projects increased, as the Company continued to progress its plans for field trials in several international markets.  Research spending increased under the Exclusive Channel Collaboration agreement with Intrexon, while general and administration costs declined due to a reduction in legal fees associated with the potential future registration and listing of the Company's shares on NASDAQ. Cash used, net of new equity funding, in the first half of 2015 was higher than the comparable period in 2014 at US$3.5 million (H1 2014: US$3.0 million). Cash and equivalents at the end of the first half of 2015 was US$4.7 million (31 December 2014: US$5.2 million).

Outlook

The Company continues to pursue the approval of its NADA for AAS and is hopeful that the decision will be received in the near term, however it has received no information on the status of FDA's finalisation of approval of the application. The Board continues to be conscious of the Company's limited cash resources and has maintained tight cost control while increasing operating activities in preparation for an approval. As stated previously, to fully implement the commercial phase, AquaBounty will require additional funding. AquaBounty continues to receive interest for its AAS from potential customers within USA as well as outside, which gives the Board confidence that the market potential for AAS is substantial.

AquaBounty Technologies, Inc.

Consolidated balance sheets

(unaudited)

AquaBounty Technologies, Inc.

Consolidated statements of operations and comprehensive loss

(unaudited)

AquaBounty Technologies, Inc.

Consolidated statements of cash flows

(unaudited)